RESEARCH
PIPELINE
Our product candidates include compounds in Phase 1, Phase 2, and Phase 3 trials for schizophrenia, autism spectrum disorders, and epilepsy.
EPIDIOLEX®(cannabidiol)
Dravet Syndrome
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Lennox-Gastaut Syndrome
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Tuberous Sclerosis Complex
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Nabiximols* *Not approved for use in the United States. Nabiximols is marketed as SATIVEX® in other countries.
MS Spasticity
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Spinal Cord Injury Spasticity
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
PTSD
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Other neurological conditions
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
CBDV
Epilepsy
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Autism Spectrum Disorders
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Other
Schizophrenia
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
Neonatal Hypoxic-Ischemic Encephalopathy
Pre-Clinic
Phase 1
Phase 2
Phase 3
Submit
Approved
In the United States, products are only approved for those indications noted as approved in the chart above. Sativex® is not approved in the United States for any indication; it is approved for MS Spasticity in certain countries outside of the United States. All other products mentioned are investigational only. See www.gwpharm.com for full details.
Medical Information
If you are a healthcare professional interested in additional scientific and clinical information on Greenwich Biosciences products, EPIDIOLEX, and cannabinoids, or would like to submit a medical request form.
EPIDIOLEX Clinical Trials
For the most up-to-date list of publicly and privately supported clinical studies of human participants treated with EPIDIOLEX.
EPIDIOLEX® (cannabidiol)
Learn about EPIDIOLEX® (cannabidiol), the first prescription formulation of highly purified, plant-derived cannabidiol (CBD).